Nilotinib, a second-generation BCR::ABL1 inhibitor, is primarily indicated for patients with chronic-phase or accelerated-phase CML who exhibit resistance or intolerance. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.